Analytical Data
-
Gene name
MGP
- Application
-
Alternative Names
Cell growth-inhibiting gene 36 protein
-
Species
Human
-
Source
E. coli
-
Tag
N- His & C- Myc
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P08493
-
Expression Region
20-96aa
-
Molecular Weight
14.5 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
MGP, or Matrix Gla Protein, is a vitamin K-dependent protein that plays a crucial role in regulating mineralization processes in the body, particularly in vascular and bone tissues. It is primarily expressed in bone and cartilage, where it inhibits the deposition of calcium phosphate crystals, thereby preventing calcification and contributing to proper skeletal development and cardiovascular health. Research into MGP has gained significant attention due to its implications in various diseases, including osteoporosis, vascular calcification, and arteriosclerosis. Studies have shown that reduced levels of MGP are associated with increased vascular stiffness and calcification, which are risk factors for cardiovascular diseases. Furthermore, MGP is involved in the inhibition of excessive mineralization, making it a potential target for therapeutic interventions aimed at treating or preventing mineral-related disorders. Understanding the mechanisms by which MGP functions, its regulatory pathways, and the influence of factors like vitamin K status and genetic polymorphisms is essential for developing strategies to harness its protective effects in health and disease. Researchers are exploring recombinant MGP (rMGP) as a promising avenue for therapeutic applications, aiming to utilize its properties to mitigate the adverse effects of dysregulated mineralization in various contexts. Overall, the comprehensive study of MGP and its recombinant forms holds significant potential for advancing our understanding of mineral metabolism and enhancing treatment options for related pathological conditions.
